These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33822401)

  • 41. Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban-A European comparative drug utilization study.
    Rottenkolber M; Schmiedl S; Ibánez L; Sabaté M; Ballarín E; Vidal X; Leon-Muñoz LM; Huerta C; Martin Merino E; Montero D; Gasse C; Andersen M; Aakjaer M; De Bruin ML; Gerlach R; Tauscher M; Souverein PC; van den Ham R; Klungel O; Gardarsdottir H;
    Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):440-454. PubMed ID: 33037766
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
    Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
    Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1653-1662. PubMed ID: 30116828
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention.
    Frol S; Sernec LP; Hudnik LK; Šabovič M; Oblak JP
    Clin Drug Investig; 2020 Nov; 40(11):1053-1061. PubMed ID: 32886321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study.
    Pottegård A; Grove EL; Hellfritzsch M
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):174-181. PubMed ID: 29141274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The changing use of anticoagulants in New Zealand.
    Harper P; Chang A; Stephens M
    N Z Med J; 2022 May; 135(1554):35-43. PubMed ID: 35728215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
    Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
    Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: a retrospective study.
    Mohan A; Majd Z; Trinh T; Paranjpe R; Abughosh SM
    Int J Clin Pharm; 2022 Aug; 44(4):966-974. PubMed ID: 35776377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation.
    Rossi AP; Facchinetti R; Ferrari E; Nori N; Sant S; Masciocchi E; Zoico E; Fantin F; Mazzali G; Zamboni M
    J Thromb Thrombolysis; 2018 Aug; 46(2):139-144. PubMed ID: 29761426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.
    Yang L; Brooks MM; Glynn NW; Zhang Y; Saba S; Hernandez I
    Am J Cardiol; 2020 Jul; 126():29-36. PubMed ID: 32359718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.
    McHorney CA; Peterson ED; Laliberté F; Germain G; Nelson WW; Crivera C; Schein J; Lefebvre P
    Clin Ther; 2016 Nov; 38(11):2477-2488. PubMed ID: 27789043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. National Trends in Ambulatory Oral Anticoagulant Use.
    Barnes GD; Lucas E; Alexander GC; Goldberger ZD
    Am J Med; 2015 Dec; 128(12):1300-5.e2. PubMed ID: 26144101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
    Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
    Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Medication adherence to direct anticoagulants in patients with non-valvular atrial fibrillation - A real world analysis.
    Brízido C; Ferreira AM; Lopes P; Strong C; Sá Mendes G; Fernandes Gama F; Durazzo A; Rocha Rodrigues G; Matos D; Guerreiro S; Madeira S; Ferreira J; Adragão P; Mendes M
    Rev Port Cardiol (Engl Ed); 2021 Sep; 40(9):669-675. PubMed ID: 34503705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.